Biotechnology industry stocks
593 companies in the Biotechnology industry. 125 have a published intrinsic value and 27 trade at least 20% below it.
The median company in Biotechnology with a published value trades 65% above our estimate of intrinsic value.
Values as of the 22 Sept 2026 close.
Most undervalued stocks in Biotechnology
- Q32 Bio Inc (QTTB): undervalued, +76% margin of safety
- Fortress Biotech Inc (FBIO): undervalued, +74% margin of safety
- CorMedix Inc (CRMD): undervalued, +73% margin of safety
- Innoviva Inc (INVA): undervalued, +71% margin of safety
- Bicycle Therapeutics Plc ADR (BCYC): undervalued, +71% margin of safety
- Legend Biotech Corp ADR (LEGN): undervalued, +63% margin of safety
- Aurinia Pharmaceuticals Inc (AUPH): undervalued, +59% margin of safety
- Adma Biologics Inc (ADMA): undervalued, +57% margin of safety
- Harmony Biosciences Holdings Inc (HRMY): undervalued, +57% margin of safety
- Immunocore Holdings plc ADR (IMCR): undervalued, +52% margin of safety
Liquid names only: at least $1M traded a day and $50M of market value.
Largest companies in Biotechnology
- Vertex Pharmaceuticals Inc (VRTX): overvalued, -36% margin of safety
- Regeneron Pharmaceuticals Inc (REGN): overvalued, -23% margin of safety
- Moderna Inc (MRNA): overvalued, -2452% margin of safety
- Argen X SE ADR (ARGX): overvalued, -27% margin of safety
- Revolution Medicines Inc (RVMD): no published value
- BeOne Medicines Ltd ADR (ONC): overvalued, -65% margin of safety
- Alnylam Pharmaceuticals Inc (ALNY): overvalued, -37% margin of safety
- Royalty Pharma plc (RPRX): overvalued, -49% margin of safety
- Roivant Sciences Ltd (ROIV): not valued
- Insmed Inc (INSM): overvalued, -887% margin of safety
- Incyte Corp (INCY): undervalued, +28% margin of safety
- BioNTech SE ADR (BNTX): not valued
- Genmab ADR (GMAB): slightly undervalued, +10% margin of safety
- Jazz Pharmaceuticals plc (JAZZ): slightly undervalued, +19% margin of safety
- Ascendis Pharma A/S (ASND): overvalued, -26% margin of safety
- Exelixis Inc (EXEL): undervalued, +36% margin of safety
- Summit Therapeutics Inc (SMMT): no published value
- BridgeBio Pharma Inc (BBIO): not valued
- Halozyme Therapeutics Inc (HALO): undervalued, +25% margin of safety
- Corcept Therapeutics Inc (CORT): overvalued, -1284% margin of safety
- Biomarin Pharmaceutical Inc (BMRN): overvalued, -57% margin of safety
- Madrigal Pharmaceuticals Inc (MDGL): not valued
- Bio-Techne Corp (TECH): overvalued, -249% margin of safety
- Twist Bioscience Corp (TWST): overvalued, -480% margin of safety
- Axsome Therapeutics Inc (AXSM): not valued
- Krystal Biotech Inc (KRYS): not valued
- Arrowhead Pharmaceuticals Inc (ARWR): overvalued, -237% margin of safety
- Kymera Therapeutics Inc (KYMR): overvalued, -1225% margin of safety
- ImmunityBio Inc (IBRX): not valued
- Cytokinetics Inc (CYTK): not valued
- Protagonist Therapeutics Inc (PTGX): overvalued, -532% margin of safety
- TG Therapeutics Inc (TGTX): overvalued, -41% margin of safety
- Caris Life Sciences Inc (CAI): not valued
- Vaxcyte Inc (PCVX): no published value
- Abivax ADR (ABVX): no published value
- Praxis Precision Medicines Inc (PRAX): no published value
- Spyre Therapeutics Inc (SYRE): no published value
- Immunovant Inc (IMVT): no published value
- Ionis Pharmaceuticals Inc (IONS): not valued
- Belite Bio Inc ADR (BLTE): no published value
- Cg Oncology Inc (CGON): not valued
- Rhythm Pharmaceuticals Inc (RYTM): not valued
- Oruka Therapeutics Inc (ORKA): no published value
- Scholar Rock Holding Corp (SRRK): no published value
- Ligand Pharmaceuticals Inc (LGND): overvalued, -162% margin of safety
- Mirum Pharmaceuticals Inc (MIRM): not valued
- CRISPR Therapeutics AG (CRSP): not valued
- Travere Therapeutics Inc (TVTX): overvalued, -65% margin of safety
- Cogent Biosciences Inc (COGT): no published value
- PTC Therapeutics Inc (PTCT): overvalued, -26% margin of safety
- Dianthus Therapeutics Inc (DNTH): not valued
- Erasca Inc (ERAS): no published value
- Definium Therapeutics Inc (DFTX): no published value
- Veradermics Inc (MANE): no published value
- Edgewise Therapeutics Inc (EWTX): no published value
- Iovance Biotherapeutics Inc (IOVA): not valued
- Viking Therapeutics Inc (VKTX): no published value
- Parabilis Medicines Inc (PBLS): no published value
- Acadia Pharmaceuticals Inc (ACAD): slightly undervalued, +16% margin of safety
- Tango Therapeutics Inc (TNGX): overvalued, -288% margin of safety
- Relay Therapeutics Inc (RLAY): not valued
- Celcuity Inc (CELC): no published value
- AbCellera Biologics Inc (ABCL): not valued
- Telix Pharmaceuticals Ltd ADR (TLX): undervalued, +33% margin of safety
- Ideaya Biosciences Inc (IDYA): overvalued, -183% margin of safety
- Xenon Pharmaceuticals Inc (XENE): no published value
- Legend Biotech Corp ADR (LEGN): undervalued, +63% margin of safety
- Tarsus Pharmaceuticals Inc (TARS): not valued
- Enliven Therapeutics Inc (ELVN): no published value
- Arcutis Biotherapeutics Inc (ARQT): not valued
- Denali Therapeutics Inc (DNLI): not valued
- Arcus Biosciences Inc (RCUS): not valued
- Dyne Therapeutics Inc (DYN): no published value
- uniQure NV (QURE): not valued
- MBX Biosciences Inc (MBX): no published value
- Zai Lab Limited ADR (ZLAB): overvalued, -94% margin of safety
- Immunome Inc (IMNM): no published value
- Precigen Inc (PGEN): not valued
- NewAmsterdam Pharma Company NV (NAMS): not valued
- AtaiBeckley Inc (ATAI): not valued
- Beam Therapeutics Inc (BEAM): overvalued, -110% margin of safety
- Nurix Therapeutics Inc (NRIX): not valued
- Structure Therapeutics Inc ADR (GPCR): no published value
- Celldex Therapeutics Inc (CLDX): not valued
- Disc Medicine Inc (IRON): no published value
- Vera Therapeutics Inc (VERA): no published value
- Mineralys Therapeutics Inc (MLYS): no published value
- Viridian Therapeutics Inc (VRDN): overvalued, -210% margin of safety
- Pharvaris NV (PHVS): no published value
- SELLAS Life Sciences Group Inc (SLS): no published value
- Harmony Biosciences Holdings Inc (HRMY): undervalued, +57% margin of safety
- Ocular Therapeutix Inc (OCUL): not valued
- Palvella Therapeutics Inc (PVLA): no published value
- Biohaven Ltd (BHVN): no published value
- Generate Biomedicines Inc (GENB): no published value
- Aurinia Pharmaceuticals Inc (AUPH): undervalued, +59% margin of safety
- Sarepta Therapeutics Inc (SRPT): not valued
- Adma Biologics Inc (ADMA): undervalued, +57% margin of safety
- Recursion Pharmaceuticals Inc (RXRX): not valued
- Trevi Therapeutics Inc (TRVI): no published value
Other Healthcare industries
All industries